Kymazol

Simvastatin, the active ingredient in Kymazol, is a HMG‑CoA reductase inhibitor presented as a strength/form for oral use. It treats hypercholesterolemia, hyperlipidemia and helps prevent cardiovascular disease in adults.\n\nGNH India supplies Kymazol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Simvastatin acts on cholesterol metabolism and is indicated for several lipid‑related conditions.\n\n- Hypercholesterolemia: lowers elevated LDL‑cholesterol and total cholesterol levels.\n- Hyperlipidemia: reduces triglycerides and improves overall lipid profile.\n- Cardiovascular disease prevention: decreases risk of myocardial infarction and stroke in patients with established risk factors.

Simvastatin may cause a range of adverse reactions, from mild to serious.\n\nCommon Side Effects:\n- Muscle pain or weakness: mild myalgia without elevated enzymes.\n- Headache: transient and usually resolves without intervention.\n- Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.\n- Elevated liver enzymes: mild transaminase increases.\n\nSerious or Rare Side Effects:\n- Rhabdomyolysis: severe muscle breakdown with possible renal impairment.\n- Hepatotoxicity: significant elevation of liver transaminases requiring discontinuation.\n- Allergic reactions: rash, pruritus or angioedema.

Before initiating therapy, consider the following precautions.\n\n- Liver function: assess baseline hepatic enzymes and monitor periodically.\n- Muscle disorders: evaluate for history of myopathy or concurrent statin use.\n- Drug interactions: review concomitant medications that may increase statin exposure.\n- Pregnancy and lactation: avoid use unless clearly indicated by a physician.\n- Renal impairment: adjust therapy in severe renal dysfunction.\n- Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Simvastatin interacts with several drug classes that can alter its plasma concentration.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may cause toxic statin levels.\n- Gemfibrozil: increases risk of myopathy and rhabdomyolysis.\n- Cyclosporine: elevates simvastatin exposure, heightening muscle toxicity.\n\nModerate Interactions (Monitor Closely):\n- Antacids (e.g., omeprazole): may modestly raise statin concentrations.\n- Warfarin: potential for enhanced anticoagulant effect; monitor INR.\n- Grapefruit juice: can increase simvastatin levels; advise limited consumption.